Hansa Biopharma, a commercial-stage biopharmaceutical company, plans to restructure the organization to better align and focus on key clinical development and commercial priorities. The planned restructuring would result in an approximately 20-25% reduction in the current workforce and will result in approximately 75-85 million Swedish Krona in annual savings when implemented. The restructuring is subject to negotiation with relevant trade unions. As part of the restructuring, Hansa will noti...